Company Profile for Cypress Bioscience Inc.Business Editors/Health/Medical Writers --(BUSINESS WIRE) Cypress (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYPB) is committed to be the innovator and leader in providing products that improve the treatment of Functional Somatic somatic /so·mat·ic/ (so-mat´ik) 1. pertaining to or characteristic of the soma or body. 2. pertaining to the body wall in contrast to the viscera. so·mat·ic adj. Syndromes, including Fibromyalgia Syndrome fibromyalgia syndrome Fibrositis, tension myalgia Psychiatry A condition characterized by muscular pain, fatigue, sleep disorders, anxiety, depression, headaches, IBS–possibly linked to anxiety and panic disorders Management Exercise, benzodiazepines, SSRIs, (FMS FMS - Flexible Manufacturing System (factory automation). ), and other related Pain and Central Nervous System conditions. Cypress' strategy involves acquiring/in-licensing undervalued Undervalued A stock or other security that is trading below its true value. Notes: The difficulty is knowing what the "true" value actually is. Analysts will usually recommend an undervalued stock with a strong buy rating. central nervous system active compounds and developing them for new indications. In January of 2004, Cypress and Forest Laboratories entered into an agreement for the development and marketing for Cypress' product, milnacipran, licensed from the product's originator, Pierre Fabre Medicament me·dic·a·ment n. An agent that promotes recovery from injury or ailment; a medicine. medicament a medicinal agent. , for indications in the United States market. Milnacipran is currently being evaluated in a Phase III program sponsored by Cypress for the treatment of Fibromyalgia Syndrome.
Company: Cypress Bioscience Inc.
Headquarters Address: 4350 Executive Drive
Suite 325
San Diego, CA 92121
Main Telephone: 858-452-2323
Website: www.cypressbio.com
Ticker: CYPB(NASDAQ)
Type of Organization: Public
Industry: Health: Biotechnology
Earnings Release Dates: 1st Quarter: May 14, 2004
2nd Quarter: August 14, 2004
Key Executives: CEO: Jay Kranzler
CFO: Sabrina Johnson
CMO: Michael Gendreau
Investor Relations
Contact: Mary Gieson
Phone: 858-452-2323
Email: investorrelations@cypressbio.com
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion